Dasatinib

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) are driven by the BCR-ABL tyrosine kinase.
• Dasatinib is a dual ABL/SRC tyrosine kinase inhibitor (TKI) targeting BCR-ABL and other kinases.
• Dasatinib demonstrates potent inhibition of BCR-ABL, offering an alternative for imatinib-resistant or intolerant CML and Ph+ ALL.

Purpose of the Study:

• To review the preclinical and clinical activity of dasatinib.
• To focus on clinical studies of dasatinib in CML treatment.
• To evaluate dasatinib's efficacy and safety in various phases of CML and in Ph+ ALL.

Main Methods:

• Review of preclinical data and clinical trial results for dasatinib.
• Analysis of randomized trial data comparing dasatinib with imatinib in CML.
• Evaluation of dosing regimens and outcomes in different CML phases and Ph+ ALL.

Main Results:

• First-line dasatinib in CML yields superior responses and improved long-term outcomes compared to imatinib.
• Once-daily dasatinib (100 mg) in chronic phase CML achieves high remission rates and prolongs survival.
• Dasatinib induces frequent complete remissions in accelerated/blastic phase CML and Ph+ ALL, though remissions may be short-lived.

Conclusions:

• Dasatinib is an effective treatment for CML and Ph+ ALL, particularly in cases resistant or intolerant to imatinib.
• First-line use of dasatinib in CML is associated with superior early and deep responses, correlating with better long-term outcomes.
• While effective, dasatinib's role in solid tumors remains under investigation, and common side effects include cytopenias and pleural effusions.